Promising new combo aims to shrink lymphoma before transplant

NCT ID NCT05821088

Recruiting now Disease control Sponsor: David Bond, MD Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated Apr 29, 2026 · Updated 14 times

Summary

This study tests a two-step treatment for people with large B-cell lymphoma that has returned or not responded to initial therapy. First, patients receive a combination of tafasitamab (an antibody that targets cancer cells) and lenalidomide (a drug that helps the immune system fight cancer). Then, they receive tafasitamab plus a standard chemotherapy regimen called ICE. The goal is to achieve complete remission before a stem cell transplant. About 37 adults who are eligible for transplant will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.